Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Identificadores
Identificadores
Visualización o descarga de ficheros
Visualización o descarga de ficheros
Fecha de publicación
2020Título de revista
BRITISH JOURNAL OF HAEMATOLOGY
Tipo de contenido
Journal Article
DeCS
supervivencia sin enfermedad | linfoma | anciano | tasa de supervivencia | mediana edad | humanos | adulto | adolescenteMeSH
Adult | Middle Aged | Humans | Disease-Free Survival | Adolescent | Lymphoma | Survival Rate | AgedResumen
Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety of switching from intravenous to subcutaneous administration of rituximab during first-line induction/maintenance for DLBCL or FL, focusing on ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients received subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4-7 cycles, and/or every 2 months maintenance monotherapy for FL for 6-12 cycles. The study included 140 patients: DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced adverse events, reaching grade >/=3 in 38.6% and were serious in 30.0%. AARs occurred in 48.6%, mostly (84.9%) at the injection site, with only 2.1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69.6%. After a median follow-up of 33.5 months, median disease-/event-/progression-free and overall survivals were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a good quality-of-life perception at induction/maintenance end. Therefore, switching to subcutaneous rituximab showed no new safety issues and maintained efficacy with improved satisfaction and quality of life.